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LETTERS TO THE EDITOR
Thoracic paraganglioma
diagnosed in a patient with
specialized  neural  crest  cells  associated  with  autonomic
ganglia  (paraganglia)  1.  Nearly  90%  of  these  tumors  arise
from  the  medulla  of  the  adrenal  gland  and  are  called
‘
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His  usual  medication  was  candesartan  16  mg,  deﬂazacortpulmonary tuberculosis -- Case
report
Paraganglioma torácico diagnosticado num
paciente com tuberculose pulmonar --
descric¸ão de caso clínicoDear  Editor,
Paragangliomas  are  rare  tumors  with  an  incidence  of
0.3--0.95%  of  neuroendocrine  tumors,  which  arise  from
Figure  1  (A)  Chest  radiography:  heterogeneous  inﬁltration  in  the  ri
(B)--(D) Chest  Computed  Tomography  of  the  thorax:  hypodense  mass
with extension  to  the  left  upper  lobe,  areas  of  consolidation  in  the  
ground-glass opacities.
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0873-2159/© 2014 Sociedade Portuguesa de Pneumologia. Published by E‘pheochromocytomas’’.  When  they  have  an  extra-adrenal
rigin,  they  are  termed  ‘‘paragangliomas’’.  Intrathoracic
ocation  is  infrequent,  corresponding  only  to  10%  of  para-
anglioma  cases.1
Herein  the  authors  described  the  case  of  a 50-year-
ld  male  patient,  Caucasian,  smoker.  As  a  background  he
ad  arterial  hypertension  and  discoid  lupus  erythematosus.ght  upper  lobe  and  homogeneous  opacity  in  the  left  hilar  region.
 of  9  cm  with  well  deﬁned  margins  located  in  the  mediastinum
right  upper  lobe  associated  with  micro-nodular  inﬁltration  and
 mg/day  and  chloroquine  250  mg/day.  He  presented  in  our
ospital  complaining  of  dyspnea,  cough,  asthenia  and  weight
oss  with  three  weeks  evolution.  His  physical  exam  was
lsevier España, S.L.U. All rights reserved.
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Figure  2  Surgical  lung  biopsy.  A  solid  and  poorly  differentiated  malignant  neoplasm  with  extensive  areas  of  necrosis  (A  --  HE  200×).
The tumor  cells  had  abundant  eosinophilic  cytoplasm  and  round  nuclei  with  evident  nucleoli  (B  --  HE  600×).  Immunohistochemically,
the neoplastic  cells  focally  expressed  vimentin  (C  --  600×)  and  synaptophysin  (D  --  600×) in  the  absence  of  epithelial  and  other
markers (AE1/AE3,  CK8/18,  CK7,  CK20,  CK5,  3412,  EMA,TTF1,  napsin-A,  p63,  calretinin,  pS100,  CD31,  CD34,  PLAP,  beta-HCG,  CD45,
CD20, CD10,  inhibin,  C-kit,  CD99,  actin,  desmin,  GFAP,  CD30,  CD21,  HMB45,  CD56,  CD23,  alpha-fetoprotein,  myeloperoxidase,
lysozyme,  WT1,  ALK,  HepPar-1).  With  those  morphological  and  immunohistochemical  characteristics  in  the  appropriate  clinical
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tontext, the  diagnostic  hypothesis  of  paraganglioma/pheochrom
nremarkable,  except  for  malar  and  cervical  cutaneous
ash  related  to  his  discoid  lupus.  Chest  X-ray  and  com-
uted  tomography  showed  pulmonary  inﬁltrations  in  the
ight  upper  lobe  and  a  mediastinic  mass  of  9  cm  (Fig.  1).
bdominal  CT  did  not  show  any  abnormalities.  Sputum  anal-
sis  conﬁrmed  a  diagnosis  of  pulmonary  tuberculosis  and
he  patient  started  anti-tuberculosis  treatment.  His  HIV
nd  hepatitis  virus  status  were  negative.  Bronchoalveo-
ar  samples  were  negative  for  malignancy  and  CT-guided
ransthoracic  core  biopsy  of  the  mediastinal  mass  only
howed  necrotic  tissue,  so  the  patient  underwent  a surgical
ung  biopsy.
Despite  treatment,  clinical  evolution  was  not  favorable,
ith  persistent  fever,  one  episode  of  auricular  ﬂutter  and
emodynamic  instability.  Antibacillary  susceptibility  testing
evealed  resistance  to  all  ﬁrst  class  drugs.  At  the  45th  day
f  admission,  patient  developed  an  acute  pulmonary  edema
ith  no  response  to  medical  treatment  and  he  eventually
ied.  Description  of  the  surgical  biopsy  was  only  available
ost-mortem  and  suggested  the  diagnosis  of  a  pheochromo-
ytoma/paraganglioma  --  Fig.  2.
This  clinical  case  illustrates  a  patient  with  concomitant
iagnosis  of  pulmonary  tuberculosis  and  a  thoracic  para-
anglioma.  Because  the  results  of  surgical  biopsy  were  only
nown  post-mortem,  additional  research  on  the  evaluation
f  the  diagnosis  of  paraganglioma,  including  determination
f  catecholamine  and  metanephrine  levels,  presence  of  dis-
ant  metastasis  and  genetic  testing  were  not  possible.
R
dtoma  was  suggested.
Because  this  is  a  rare  tumor,  most  of  the  literature
escribes  only  single  case  reports.2,3 In  2008,  Mayo  Clinic
eported  their  experience  with  fourteen  cases  of  treated
ediastinal  paragangliomas.4 Concomitant  occurrence  of
uberculosis  and  thoracic  paraganglioma  is  even  rarer,  with
ery  few  previous  reports5,  making  the  diagnosis  and  treat-
ent  of  these  cases  difﬁcult  and  challenging.
In  conclusion,  paragangliomas  are  not  usually  suspected
n  the  initial  evaluation  of  a  mediastinal  mass  because  of  its
arity,  but  it  should  be  part  of  the  differential  diagnosis.  The
oncomitant  occurrence  of  tuberculosis  may  pose  a  diagnos-
ic  challenge  in  this  case,  leading  to  a  delay  in  the  diagnosis
f  this  type  of  tumors.
thical considerations
rotection  of  people  and  animals.  The  authors  declare  that
o  experiments  were  performed  on  humans  or  animals  for
his  study.
onﬁdentiality  of  data.  The  authors  declare  that  they  have
ollowed  the  protocols  of  their  work  center  on  the  publica-
ion  of  patient  data.ight  to  privacy  and  informed  consent.  The  authors
eclare  that  no  patient  data  appear  in  this  publication.
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Ethical limits for noninvasive
ventilation prescription
Limites éticos para a prescric¸ão de ventilac¸ão
não invasiva
To  the  Editor:
Non-Invasive  Ventilation  (NIV)  is  the  treatment  of  choice  in
acute  respiratory  failure  (ARF)  related  to  Chronic  Obstruc-
tive  Pulmonary  Disease  exacerbation  and  Acute  Cardiogenic
Pulmonary  Edema.1,2 It  has  also  demonstrated  good  results
in  a  set  of  other  consensual  and  systematized  pathologies.1,2
In  addition  NIV  has  been  used  as  an  alternative  for  ARF
patients  who  have  ‘‘do-not-intubate’’  orders  either  due
to  poor  prognosis  associated  with  multiple  comorbidi-
ties  or  terminal  disease,  or  as  palliative  management  of
dyspnea.2
Aiming  to  encourage  discussion  around  this  theme,  the
authors  reviewed  508  medical  records  of  patients  undergo-
ing  NIV  between  November  2011  and  May  2013,  in  Hospital
Geral  do  Centro  Hospitalar  e  Universitário  de  Coimbra,  and
of  central  origin.  The  patients,  4  male  and  11  females,  had
an  average  age  of  65  ±  15,  and  had  an  average  age-adjusted
Charlson  comorbidity  index  of  6.5  ±  3.1.  Five  patients  pre-
sented  type  1  RF,  and  9  had  type  2  RF.  NIV  was  administered
to  one  patient  despite  a  lack  of  RF  criteria.  The  average
PaO2/FiO2 ratio  was  187.9  ±  60.2,  and  average  PaCO2 was
58.3  ±  25.0  mmHg.  Seven  patients  presented  acidosis  (aver-
age  pH:  7.19  ±  0.13):  mixed  in  4  cases,  respiratory  in  2,  and
metabolic  in  one  patient.  The  application  of  pressure  sup-
port  ventilation  of  11.4  ±  2.8  cmH2O,  with  50.4  ±  21.7%  FiO2
led  to  improved  pH,  PaO2/FiO2 and  PaCO2 but  showed  no
statistical  signiﬁcance  (Table  1).  After  3.0  ±  4.2  days  of  NIV
13  of  the  15  patients  died.  None  of  the  10  patients  capa-
ble  of  assessing  the  efﬁcacy  subjectively  referred  relief  of
dyspnea.
In  conclusion,  we  do  not  consider  it  appropriate
to  use  NIV  in  situations  where  there  is  no  legitimate
justiﬁcation.  On  the  contrary:  it  is  an  inefﬁcient  and  costly
approach  and  often  leads  to  misperceptions  about  end  of
life  management.3 With  our  limited  public  health  resources
providing  differentiated  treatments  to  those  who  do  not
beneﬁt  from  them  could  be  considered  ethically  repre-
hensible  because,  as  a  consequence,  treatment  may  notidentiﬁed  15  cases  in  which  the  use  of  NIV  was  the  subject
of  ethical  considerations:  6  patients  with  advanced  cancer
disease,  5  with  multiple  organ  dysfunction,  3  with  extensive
stroke  damage,  and  one  patient  with  respiratory  failure  (RF)
Table  1  Arterial  Blood  Gas  (ABG)  parameters  evolution.
Parameters  Baseline  After  NIV  trial  P  value
pH  7.31  ±  0.18  7.36  ±  0.11  0.600
PaCO2 (mmHg)  58.3  ±  25.0  51.9  ±  12.7  0.507
PaO2/FiO2 187.9  ±  60.2  192.25  ±  67.2  0.882
NIV, non-invasive ventilation.
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2hen  be  available  for  those  who  would  beneﬁt.  NIV  can  on
ccasions  contribute  to  a patient’  comfort,  when  combined
ith  other  measures  (like  administration  of  morphine)  in
he  appropriate  institutions,  but  not  in  hospital  emergency
oom.
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